DK1360202T3 - Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser - Google Patents

Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser

Info

Publication number: DK1360202T3
Authority: DK; Denmark
Prior art keywords: disorders; glp; glucagon; peptide; prolonged
Prior art date: 2001-02-16

Application number

DK02700079T

Other languages

English (en)

Inventor

Karen Thibaudeau

Dominique P Bridon

Nissab Boudjellab

Roger Leger

Martin Robitaille

Julie Carette

Original Assignee

Conjuchem Biotechnologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-16

Filing date

2002-02-15

Publication date

2008-09-22

2002-02-15 Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc

2008-09-22 Application granted granted Critical

2008-09-22 Publication of DK1360202T3 publication Critical patent/DK1360202T3/da

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title 2
102100040918 Pro-glucagon Human genes 0.000 title 2
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title 2
208000018522 Gastrointestinal disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000035475 disorder Diseases 0.000 title 1
230000002035 prolonged effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK02700079T 2001-02-16 2002-02-15 Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser DK1360202T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26927601P	2001-02-16	2001-02-16
PCT/CA2002/000175 WO2002066511A2 (en)	2001-02-16	2002-02-15	Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders

Publications (1)

Publication Number	Publication Date
DK1360202T3 true DK1360202T3 (da)	2008-09-22

Family

ID=23026568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02700079T DK1360202T3 (da)	2001-02-16	2002-02-15	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser

Country Status (14)

Country	Link
US (3)	US7112567B2 (da)
EP (2)	EP1360202B1 (da)
JP (4)	JP4280070B2 (da)
AP (1)	AP1886A (da)
AT (1)	ATE396202T1 (da)
AU (1)	AU2002233089B2 (da)
CA (1)	CA2436399A1 (da)
CY (1)	CY1108274T1 (da)
DE (1)	DE60226702D1 (da)
DK (1)	DK1360202T3 (da)
EA (1)	EA006160B1 (da)
ES (1)	ES2307718T3 (da)
PT (1)	PT1360202E (da)
WO (1)	WO2002066511A2 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7601691B2 (en)	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
SI1180121T1 (en) *	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US20040266673A1 (en) *	2002-07-31	2004-12-30	Peter Bakis	Long lasting natriuretic peptide derivatives
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6887470B1 (en)	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ATE396202T1 (de) *	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
US20030119734A1 (en) *	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
WO2004035624A2 (en) *	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
WO2004085471A2 (en) *	2003-03-24	2004-10-07	Novo Nordisk A/S	Glp-2 derivatives
JP4936884B2 (ja) *	2003-06-03	2012-05-23	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
WO2004105790A1 (en) *	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
PT1687019T (pt) *	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
CA2564031A1 (en) *	2004-04-23	2005-11-03	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
EP1789434B1 (en) *	2004-08-31	2013-11-20	Novo Nordisk A/S	Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US7847061B2 (en)	2004-11-01	2010-12-07	Nps Pharmaceuticals, Inc.	Treatment of short bowel syndrome patients with colon-in-continuity
EP2494983B1 (en) *	2004-11-12	2019-04-24	Novo Nordisk A/S	Stable formulations of glp-1
US8088508B2 (en)	2005-01-31	2012-01-03	Panasonic Corporation	Thermal battery
MX2007013431A (es)	2005-05-04	2008-01-18	Zealand Pharma As	Analogos del peptido 2 semejante al glucagon.
JP2009514508A (ja) *	2005-10-24	2009-04-09	セントカー・インコーポレーテツド	Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
US8039432B2 (en) *	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) *	2008-06-27	2012-05-15	Duke University	Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
JP5290177B2 (ja) *	2006-08-31	2013-09-18	セントカー・インコーポレーテツド	Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
US20090099074A1 (en) *	2007-01-10	2009-04-16	Conjuchem Biotechnologies Inc.	Modulating food intake
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
WO2009033746A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
US20090186819A1 (en) *	2007-12-11	2009-07-23	Marieve Carrier	Formulation of insulinotropic peptide conjugates
EP2311486A1 (en) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en) *	2009-10-23	2011-04-27	Ferring B.V.	Peptidic GLP-2 agonists
EP2611825B1 (en) *	2010-08-30	2015-09-02	NPS Pharmaceuticals, Inc.	Solid phase synthesis of h(gly2)glp-2
KR101895047B1 (ko) *	2011-12-30	2018-09-06	한미사이언스 주식회사	면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
TR201802689T4 (tr)	2012-05-03	2018-03-21	Zealand Pharma As	Glukagon benzeri peptit-2 (glp-2) analogları.
KR20220051197A (ko)	2012-05-17	2022-04-26	익스텐드 바이오사이언시즈, 인크.	개선된 약물 전달용 캐리어
WO2016065052A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Insulin vitamin d conjugates
US9789197B2 (en)	2014-10-22	2017-10-17	Extend Biosciences, Inc.	RNAi vitamin D conjugates
US9585934B2 (en)	2014-10-22	2017-03-07	Extend Biosciences, Inc.	Therapeutic vitamin D conjugates
EP4442314A2 (en) *	2015-10-28	2024-10-09	Tufts University	Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
HUE064463T2 (hu)	2016-07-11	2024-03-28	Opko Biologics Ltd	Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
CA3090767A1 (en)	2017-02-27	2018-08-30	Urigen N.A.	Treatment of lower urinary tract epithelium with glucagon like peptide 2
ES2894629T3 (es)	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
HUE066356T2 (hu)	2017-08-24	2024-07-28	Novo Nordisk As	GLP-1 készítmények és alkalmazásaik
EP3689898B1 (en)	2017-09-28	2026-04-29	Hanmi Pharm. Co., Ltd.	Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative
CN108395469A (zh) *	2018-02-01	2018-08-14	滨海吉尔多肽有限公司	一种假脯氨酸二肽的合成方法
WO2020020904A1 (en)	2018-07-23	2020-01-30	Zealand Pharma A/S	Therapeutic uses of glp-2 agonists
EP3628682A1 (en)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20200254065A1 (en) *	2019-02-11	2020-08-13	Opko Biologics Ltd.	Long-acting glp-2 analogs
BR112022006546A2 (pt)	2019-10-07	2022-08-30	Kallyope Inc	Agonistas de gpr119
PE20221575A1 (es)	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas
CA3173731A1 (en)	2020-02-28	2021-09-02	Kallyope, Inc.	Gpr40 agonists
CN116323608A (zh)	2020-05-19	2023-06-23	卡尔优普公司	Ampk活化剂
EP4172162A4 (en)	2020-06-26	2024-08-07	Kallyope, Inc.	AMPK ACTIVATORS
EP4593867A2 (en)	2022-09-30	2025-08-06	Extend Biosciences, Inc.	Long-acting parathyroid hormone

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1160380A (en) *	1966-12-22	1969-08-06	Ford Motor Co	Vehicle Engine Arrangement.
US3719667A (en)	1970-08-24	1973-03-06	Lilly Co Eli	Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en)	1971-05-28	1974-10-08	Lilly Co Eli	Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
DE3241416A1 (de) *	1982-01-19	1983-07-28	Josef Gartner & Co, 8883 Gundelfingen	Isolierverglasung
US4462941A (en)	1982-06-10	1984-07-31	The Regents Of The University Of California	Dynorphin amide analogs
DK608589D0 (da)	1989-12-01	1989-12-01	Holm Arne	Kemisk fremgangsmaade
US5843440A (en)	1990-10-03	1998-12-01	Redcell Canada, Inc.	Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en)	1990-10-03	1997-03-18	Redcell, Inc.	Super-globuling for in vivo extended lifetimes
CA2106314A1 (en)	1991-04-05	1992-10-06	John P. Burnier	Platelet aggregation inhibitors having high specification for gpiibiiia
DE4122210C2 (de)	1991-07-04	1999-04-01	Deutsches Krebsforsch	Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
WO1993025217A1 (en)	1992-06-12	1993-12-23	Des-Tyr Dynorphin Partnership	Des-tyr dynorphin analogues
EP0602290B1 (en)	1992-12-04	1999-08-25	ConjuChem, Inc.	Antibody-conjugated Hepatitis B surface antigen and use thereof
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5580853A (en)	1994-03-22	1996-12-03	New England Deaconess Hospital	Modified polypeptides with increased biological activity
US5496007A (en) *	1994-05-13	1996-03-05	Reece; Cecil L.	Device for holding out-sized documents
AU7637394A (en)	1994-08-26	1996-03-22	Avram Goldstein	Analgesic method with dynorphin analogues truncated at the n-terminus
US5789379A (en) *	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5654276A (en)	1995-06-07	1997-08-05	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-5 receptor
JP2000504316A (ja)	1996-01-12	2000-04-11	コンジュケムインコーポレイテッド	診断造影用の細胞蛋白質及び血清蛋白質アンカー
US6277583B1 (en)	1996-02-07	2001-08-21	Conjuchem, Inc.	Affinity labeling libraries and applications thereof
AU723694B2 (en)	1996-06-05	2000-08-31	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation and medicaments containing them
US5840733A (en)	1996-07-01	1998-11-24	Redcell, Canada, Inc.	Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
DE69739172D1 (de)	1996-08-08	2009-01-29	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
AU4112497A (en) *	1996-08-30	1998-03-19	Novo Nordisk A/S	Glp-2 derivatives
AU4351897A (en)	1996-09-16	1998-04-02	Conjuchem, Inc.	Affinity labeling libraries with tagged leaving groups
DK1012186T3 (da) *	1996-12-06	2002-11-04	Amgen Inc	Keratinocyt-vækstfaktorer og anvendelser deraf
US5952301A (en)	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
US6723530B1 (en)	1997-02-05	2004-04-20	Amylin Pharmaceuticals, Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
US6051557A (en)	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
DK1019077T4 (da)	1997-08-08	2011-03-07	Amylin Pharmaceuticals Inc	Hidtil ukendte exendinagonistforbindelser
JP2001522863A (ja)	1997-11-07	2001-11-20	コンジュケム，インコーポレーテッド	Ｒｇｄ含有ペプチドおよび内因性担体の新規コンジュゲート
ATE218892T1 (de)	1997-11-07	2002-06-15	Conjuchem Inc	Affinitätsmarkierer für menschliches serum albumin
US6437092B1 (en)	1998-11-06	2002-08-20	Conjuchem, Inc.	Conjugates of opioids and endogenous carriers
WO1999024015A1 (en)	1997-11-12	1999-05-20	Alza Corporation	Buffered drug formulations for transdermal electrotransport delivery
JP2001523688A (ja)	1997-11-14	2001-11-27	アミリン・ファーマシューティカルズ，インコーポレイテッド	新規エキセンジン・アゴニスト化合物
JP2003522721A (ja)	1997-11-14	2003-07-29	アミリン・ファーマシューティカルズ，インコーポレイテッド	新規なエキセンジンアゴニスト化合物
WO1999043708A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504527A (ja)	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en)	1998-03-17	2000-08-22	Conjuchem, Inc.	Extended lifetimes in vivo renin inhibitors
US20030170250A1 (en)	1998-03-23	2003-09-11	Ezrin Alan M.	Local delivery of long lasting therapeutic agents
CA2291066A1 (en)	1998-03-23	1999-09-30	Conjuchem, Inc.	Local delivery of long lasting therapeutic agents
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
BR0010757A (pt)	1999-05-17	2002-02-19	Conjuchem Inc	Inibidores de peptìdeo de fusão de longa duração de infecção viral
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US7144854B1 (en)	1999-09-10	2006-12-05	Conjuchem, Inc.	Long lasting anti-angiogenic peptides
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
EP1623994A3 (en) *	1999-05-17	2008-07-16	ConjuChem Biotechnologies Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en)	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en)	2002-07-31	2004-12-30	Peter Bakis	Long lasting natriuretic peptide derivatives
JP4209086B2 (ja)	1999-05-17	2009-01-14	コンジュケムバイオテクノロジーズインコーポレイテッド	長期持続性抗新脈管形成ペプチド
US6849714B1 (en)	1999-05-17	2005-02-01	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en)	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
DE19926154A1 (de)	1999-06-09	2000-12-14	Ktb Tumorforschungs Gmbh	Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de)	1999-06-10	2000-12-14	Ktb Tumorforschungs Gmbh	Träger-Pharmaka-Konjugate
CA2383794A1 (en)	1999-09-07	2001-03-15	Conjuchem Inc.	Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
US6706892B1 (en)	1999-09-07	2004-03-16	Conjuchem, Inc.	Pulmonary delivery for bioconjugation
US7090851B1 (en)	1999-09-10	2006-08-15	Conjuchem Inc.	Long lasting fusion peptide inhibitors of viral infection
DE10012120A1 (de)	2000-03-13	2001-09-27	Ktb Tumorforschungs Gmbh	Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CN1491233A (zh)	2001-02-02	2004-04-21	康久化学公司	长效生长激素释放因子衍生物
ATE396202T1 (de)	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DK1479691T3 (da)	2001-05-31	2007-03-12	John Erickson	Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
US6882816B2 (en) *	2002-02-19	2005-04-19	Matsushita Electric Industrial Co., Ltd.	Developing device with developer circulating path
AU2003246500A1 (en)	2002-07-31	2004-02-16	Conjuchem Biotechnologies Inc.	Long lasting natriuretic peptide derivatives
DE602004021603D1 (de)	2003-07-25	2009-07-30	Conjuchem Biotechnologies Inc	Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
CA2564031A1 (en)	2004-04-23	2005-11-03	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP1976876A4 (en)	2005-12-22	2010-01-13	Conjuchem Biotechnologies Inc	PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT

2002
- 2002-02-15 AT AT02700079T patent/ATE396202T1/de active
- 2002-02-15 JP JP2002566224A patent/JP4280070B2/ja not_active Expired - Lifetime
- 2002-02-15 PT PT02700079T patent/PT1360202E/pt unknown
- 2002-02-15 AU AU2002233089A patent/AU2002233089B2/en not_active Ceased
- 2002-02-15 EP EP02700079A patent/EP1360202B1/en not_active Expired - Lifetime
- 2002-02-15 DE DE60226702T patent/DE60226702D1/de not_active Expired - Lifetime
- 2002-02-15 CA CA002436399A patent/CA2436399A1/en not_active Abandoned
- 2002-02-15 US US10/203,808 patent/US7112567B2/en not_active Expired - Fee Related
- 2002-02-15 EP EP08156596A patent/EP1980572A1/en not_active Withdrawn
- 2002-02-15 ES ES02700079T patent/ES2307718T3/es not_active Expired - Lifetime
- 2002-02-15 WO PCT/CA2002/000175 patent/WO2002066511A2/en not_active Ceased
- 2002-02-15 EA EA200300857A patent/EA006160B1/ru not_active IP Right Cessation
- 2002-02-15 DK DK02700079T patent/DK1360202T3/da active
- 2002-11-13 AP AP2005003310A patent/AP1886A/xx active
2005
- 2005-12-23 US US11/318,323 patent/US7737251B2/en not_active Expired - Fee Related
2008
- 2008-03-28 JP JP2008088237A patent/JP2008179652A/ja active Pending
- 2008-08-20 CY CY20081100886T patent/CY1108274T1/el unknown
- 2008-10-10 JP JP2008264644A patent/JP2009035568A/ja not_active Withdrawn
2009
- 2009-07-19 US US12/505,506 patent/US20090312259A1/en not_active Abandoned
2010
- 2010-03-03 JP JP2010046750A patent/JP2010150276A/ja active Pending

Also Published As

Publication number	Publication date
US7737251B2 (en)	2010-06-15
ATE396202T1 (de)	2008-06-15
PT1360202E (pt)	2008-09-01
EP1360202A2 (en)	2003-11-12
EA006160B1 (ru)	2005-10-27
JP2008179652A (ja)	2008-08-07
US7112567B2 (en)	2006-09-26
JP2009035568A (ja)	2009-02-19
WO2002066511A2 (en)	2002-08-29
CA2436399A1 (en)	2002-08-29
CY1108274T1 (el)	2014-02-12
AP1886A (en)	2008-09-20
AU2002233089B2 (en)	2005-12-22
EP1980572A1 (en)	2008-10-15
JP4280070B2 (ja)	2009-06-17
US20060217304A1 (en)	2006-09-28
US20090312259A1 (en)	2009-12-17
AP2005003310A0 (en)	2005-06-30
EP1360202B1 (en)	2008-05-21
JP2004532819A (ja)	2004-10-28
EA200300857A1 (ru)	2003-12-25
WO2002066511A3 (en)	2003-03-06
US20040248782A1 (en)	2004-12-09
DE60226702D1 (de)	2008-07-03
ES2307718T3 (es)	2008-12-01
JP2010150276A (ja)	2010-07-08

Publication	Publication Date	Title
PT1360202E (pt)	2008-09-01	Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
IS2625B (is)	2010-05-15	4(fenýl-píperasinýl-metýl)bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
DK1286668T3 (da)	2005-08-15	Farmaceutiske kombinationer indeholdende tegaserod og omeprazol og deres anvendelse til behandling af gastrointestinale sygdomme
IS7189A (is)	2004-03-19	Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra
IS7185A (is)	2004-03-16	Glúkagon-líkir-peptíð-1 hermar í mönnum og notkunþeirra við meðhöndlun sykursýki og skylds ástands
NO20040246L (no)	2004-04-01	TACI'er- og BR3-polypeptider og anvendelser derav
EP1372739A4 (en)	2005-10-19	STABILIZED THERAPEUTIC AND IMAGING AGENTS
IS2457B (is)	2008-11-15	Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
NO20033123D0 (no)	2003-07-08	Terapeutisk hinnedannende sammensetning og behandlingsplan derav
EP1406493A4 (en)	2006-06-14	ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS7863A (is)	2005-05-25	4 (fenýl-píperasínýl-metýl)bensamíðafleiður og notkun þeirra til að meðhöndla verk eða sjúkdóma í maga og görnum
IS7026A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
EP1462455A4 (en)	2008-12-31	NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS
NO20023448L (no)	2002-09-17	Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
IS7864A (is)	2005-05-25	4(fenýl-píperasínýl-metýl)bensamíðafleiður og notkun þeirra til að meðhöndla verk eða sjúkdóma í maga og görnum
DK1408949T3 (da)	2008-04-28	Glycinbetain og dets brugområde for opfindelsen
IS7027A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
AU2003278664A1 (en)	2004-06-07	4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
IS7025A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
DK1357910T3 (da)	2005-08-08	Fremgangsmåde til forebyggelse og behandling af smerter i de indre organer og mavetarmlidelser
IS7028A (is)	2003-11-12	4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IS7029A (is)	2003-11-12	4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IS7024A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum